Alivexis, Inc.

Alivexis, Inc. is a biotechnology company focused on developing small-molecule targeted therapeutics, utilizing advanced technologies to improve treatment precision for serious medical conditions. Alivexis, Inc. specializes in the development of innovative therapeutics, founded in 2017 in Tokyo, Japan.

The company has completed 1 deal to date, with the most recent transaction occurring on January 7, 2025. The firm attracted attention through its Series D funding round of JPY 800 million, raised with contributions from DBJ Capital, Fast Track Initiative, and JIC Venture Growth Investments. The founder, whose prior ventures are not specified, has played a critical role in the company's strategy and evolution. Alivexis, Inc.

specializes in the development of small-molecule targeted therapeutics, leveraging its proprietary technology platform and extensive biological insights. The company focuses on addressing challenging biological targets through advanced structural analysis and supercomputing technologies, which enhance the precision and efficacy of their therapeutic candidates. These products are designed to accelerate the delivery of innovative treatments to patients and families facing serious medical conditions. Alivexis serves a global client base that includes pharmaceutical companies and healthcare providers across North America, Europe, and Asia, aiming to improve patient outcomes through its breakthrough therapies.

Alivexis, Inc. generates revenue through strategic partnerships and collaborations within the pharmaceutical and biotechnology sectors. The company engages in direct business transactions with clients that may involve licensing agreements for its therapeutic candidates or collaborative research initiatives. Revenue streams are structured around milestone payments, royalties from successful drug developments, and potential subscription models for ongoing access to their technology platform.

The company’s flagship products are integrated into broader therapeutic portfolios managed by their partners, ensuring that Alivexis remains an essential player in the drug discovery landscape. In January 2025, Alivexis, Inc. raised JPY 800 million in Series D funding to bolster its research and development initiatives. The company plans to utilize this funding to enhance current offerings, including the ModBindTM, and to support the design and launch of new products.

Furthermore, Alivexis aims to expand into new markets, particularly targeting regions in Europe and Asia by 2026, thereby increasing its global footprint in the biotechnology sector.